Trial Profile
A randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy and safety of two doses of oral microencapsulated grass pollen extract administered prior to and during the the grass pollen season.
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2012
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Curalogic
- 24 Mar 2012 Planned end date changed from 23 Oct 2008 to 1 Nov 2008 as reported by European Clinical Trials Database.
- 24 Mar 2012 Actual initiation date changed from 23 Oct 2007 to 1 Nov 2007 as reported by European Clinical Trials Database.
- 24 Aug 2011 This trial is recruiting in France and has discontinued in Latvia, Denmark, Germany, Czech Republic.